Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life

Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life

Abstract Introduction In 2017, all people with severe hemophilia B in Ireland switched to recombinant factor IX Fc fusion protein concentrate (rFIXFc) prophylaxis. Patient‐reported outcomes (PROs) and health‐related quality of life (HRQoL) are important to evaluate with new treatments. Aims To asses...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mairead O’Donovan, Eimear Quinn, Kate Johnston, Evelyn Singleton, Julie Benson, Brian O'Mahony, Declan Noone, Cleona Duggan, Ruth Gilmore, Kevin Ryan, James S. O'Donnell, Niamh M. O’Connell
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
extended half‐life concentrate
hemophilia B
health‐related quality of life
pain
patient‐reported outcomes
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/cce7db211eaf4a6f804488289b87edbe
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/cce7db211eaf4a6f804488289b87edbe

Ejemplares similares